Latest News

Newsletter April 2017

CEO’s comments I hope that you have all had a happy and pleasant Easter, even if the weather was rather patchy at times. In March and April, Cyxone, together with researchers in Vienna, Freiburg and our strategic partner Sourcia, processed the results of the T20K study with a view to developing a coherent plan to […]

Read More

Newsletter March 2017

This issue of the newsletter is a little later than planned due to two international events, Swiss Nordic Bio and Sachs Forum, which were held in the past two months. Because I presented Cyxone and how T20K can combat MS in presentations at both events, a certain degree of preparation was necessary to deliver as […]

Read More

Newsletter February 2017

A message from the CEO We learnt a great deal about T20K in 2016! Over the past six months, we have analysed a number of T20K’s key characteristics according to the plans we announced prior to floatation in June 2016. We now know that T20K is easier to chemically synthesize, and it appears to be […]

Read More

Newsletter January 2017

CEO comments December has been very busy due to Christmas holidays and because many results had to be brought in from our collaborative partners to start our planning for year 2017. Thanks to Cyxone’s new project manager Leonard Saffer, the process worked very well and we are looking forward to a new, exciting year with […]

Read More

Newsletter December 2016

Message from the CEO The month began with BioEurope in Cologne, where we had meetings with new pharmaceutical companies and companies that can coordinate Cyxone’s regulatory studies (CROs). I met representatives from pharmaceutical companies that are very active in Multiple Sclerosis (MS) and had very good discussions about T20K and Multiple Sclerosis. I also had […]

Read More